Please login to the form below

Not currently logged in
Email:
Password:

Gyros Protein Technologies appoints chairman

Dr Frank Witney brings experience from Affymetrix and Dionex

Gyros Protein Technologies Dr Frank WitneySwedish Gyros Protein Technologies has appointed Dr Frank Witney as the new chairman of its board, succeeding David Patteson.

Dr Witney brings over 30 years of leadership experience in the life sciences industry, most recently having served as president and chief executive officer of Affymetrix.

He has held a number of executive roles in recent years, including serving as president and chief executive of both Dionex and Panomics, and was Packard Biosciences' chief operating officer before becoming president of life sciences after the firm's acquisition by Perkin Elmer.

Dan Calvo, Gyros Protein Technologies' chief executive, said: “We are delighted that Frank has joined as chairman.

“He brings with him a wealth of experience and knowledge in the field, and his guidance will be invaluable as we work to build Gyros Protein Tehcnologies following the merger earlier this year.”

23rd June 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...